Epigenetic silencing of DUSP9 induces the proliferation of human gastric cancer by activating JNK signaling

Oncology Reports

Volumn 34, Issue 1, 2015, Pages 121-128

  Wu, Fang ^a,b   Lv, Tianmin ^c   Chen, Gang ^b   Ye, Huajun ^b   Wu, Wei ^b   Li, Gang ^b   Zhi, Fa Chao ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c HUZHOU UNIVERSITY   (China)

Author keywords

DNA methylation; DUSP9; Gastric cancer; JNK signaling; Proliferation

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DUAL SPECIFICITY PHOSPHATASE 9; JANUS KINASE; PROTEIN C JUN; PROTEIN P21; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; DUAL SPECIFICITY PHOSPHATASE; DUSP9 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYCLIN D1 GENE; DISEASE ACTIVITY; DNA METHYLATION; DOWN REGULATION; DUAL SPECIFICITY PHOSPHATASE 9 GENE; ENZYME ACTIVATION; EPIGENETICS; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE SILENCING; HUMAN; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; UPREGULATION; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ANTHRACENES; CELL LINE, TUMOR; CELL PROLIFERATION; CPG ISLANDS; DNA METHYLATION; DUAL-SPECIFICITY PHOSPHATASES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS;

EID: 84930032915     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3998     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet 374: 477-490, 2009.
3. Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J and Sung JJ: Dysregulation of cellular signaling in gastric cancer. Cancer Lett 295: 144-153, 2010.
4. Venerito M, Nardone G, Selgrad M, Rokkas T and Malfertheiner P: Gastric cancer - epidemiologic and clinical aspects. Helicobacter 19 (Suppl 1): 32-37, 2014.
5. Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549, 2009.
6. Dong HW, Zhang S, Sun WG, Liu Q, Ibla JC, Soriano SG, Han XH, Liu LX, Li MS and Liu JR: β-ionone arrests cell cycle of gastric carcinoma cancer cells by a MAPK pathway. Arch Toxicol 87: 1797-1808, 2013.
7. Chen P, Zhao D, Sun Y, Huang L, Zhang S and Yuan Y: Protein inhibitor of activated STAT-1 is downregulated in gastric cancer tissue and involved in cell metastasis. Oncol Rep 28: 2149-2155, 2012.
8. Chen L, Hu W, Tan S, Wang M, Ma Z, Zhou S, Deng X, Zhang Y, Huang C, Yang G, et al: Genome-wide identification and analysis of MAPK and MAPKK gene families in Brachypodium distachyon. PLoS One 7: e46744, 2012.
9. Berlier JL, Rigutto S, Dalla Valle A, Lechanteur J, Soyfoo MS, Gangji V and Rasschaert J: Adenosine triphosphate prevents serum deprivation-induced apoptosis in human mesenchymal stem cells via activation of the MAPK signaling pathways. Stem Cells 33: 211-218, 2015.
10. Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290, 2007.
11. Chen Z, Cai Y, Zhang W, Liu X and Liu S: Astragaloside IV inhibits platelet-derived growth factor-BB-stimulated proliferation and migration of vascular smooth muscle cells via the inhibition of p38 MAPK signaling. Exp Ther Med 8: 1253-1258, 2014.
12. Bernardo-Faura M, Massen S, Falk CS, Brady NR and Eils R: Data-derived modeling characterizes plasticity of MAPK signaling in melanoma. PLoS Comput Biol 10: e1003795, 2014.
13. Park GB, Choi Y, Kim YS, Lee HK, Kim D and Hur DY: ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in sorafenib-induced apoptosis of EBV-transformed B cells. Int J Oncol 44: 977-985, 2014.
14. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632, 1998.
15. Caunt CJ and Keyse SM: Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. FEBS J 280: 489-504, 2013.
16. Wu GS: Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev 26: 579-585, 2007.
17. Keyse SM: Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27: 253-261, 2008.
18. Muda M, Boschert U, Smith A, Antonsson B, Gillieron C, Chabert C, Camps M, Martinou I, Ashworth A and Arkinstall S: Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4. J Biol Chem 272: 5141-5151, 1997.
19. Liu Y, Lagowski J, Sundholm A, Sundberg A and Kulesz-Martin M: Microtubule disruption and tumor suppression by mitogen-activated protein kinase phosphatase 4. Cancer Res 67: 10711-10719, 2007.
20. Wu S, Wang Y, Sun L, Zhang Z, Jiang Z, Qin Z, Han H, Liu Z, Li X, Tang A, et al: Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma. BMC Cancer 11: 413, 2011.
21. Liu J, Ni W, Xiao M, Jiang F and Ni R: Decreased expression and prognostic role of mitogen-activated protein kinase phosphatase 4 in hepatocellular carcinoma. J Gastrointest Surg 17: 756-765, 2013.
22. Jenner S, Wiedorn KH and Techel D: Development of a DUSP9 methylation screening assay. Pathol Oncol Res 21: 123-130, 2015.
23. Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431, 2002.
24. Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196, 1998.
25. Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16: 168-174, 2000.
26. Palau A, Perucho M, Esteller M and Buschbeck M: First Barcelona conference on epigenetics and cancer. Epigenetics 9: 468-475, 2014.
27. Liu G, Liu YJ, Lian WJ, Zhao ZW, Yi T and Zhou HY: Reduced BMP6 expression by DNA methylation contributes to EMT and drug resistance in breast cancer cells. Oncol Rep 32: 581-588, 2014.
28. Minning C, Mokhtar NM, Abdullah N, Muhammad R, Emran NA, Ali SA, Harun R and Jamal R: Exploring breast carcinogenesis through integrative genomics and epigenomics analyses. Int J Oncol 45: 1959-1968, 2014.
29. Vizoso M and Esteller M: German-Catalan workshop on epigenetics and cancer. Epigenetics 8: 998-1003, 2013.
30. Esteller M: Epigenetics in cancer. N Engl J Med 358: 1148-1159, 2008.
31. Guerrero-Preston R, Hadar T, Ostrow KL, Soudry E, Echenique M, Ili-Gangas C, Pérez G, Perez J, Brebi-Mieville P, Deschamps J, et al: Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncol Rep 32: 505-512, 2014.